ArticleIBRO neuroscience reports2024
Exploration of demographic prevalence of mild cognitive impairment using Montreal cognitive assessment: A cross-sectional pilot study in the Cape Coast Metropolis, Ghana.
Article in IBRO neuroscience reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic potential of near-infrared spectroscopy in mild cognitive impairment and neurodegenerative disorders: Implications for resource-limited settings.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Peripheral oxidative stress related biomarkers in Alzheimer's disease: A systematic review of their implications for diagnosis and disease monitoring.Alzheimer's & dementia (Amsterdam, Netherlands)Review
- Population disparities in Alzheimer's disease: A systematic review of fluid and neuroimaging biomarkers.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Global prevalence of dementia is projected to rise, particularly in low and middle-income countries like Ghana. Mild cognitive impairment (MCI), an intermediate phase between normal cognitive aging and dementia, is characterized by an objective and subjective decline in cognitive abilities. Individuals with MCI have a greater likelihood of progression to dementia. Purpose: There is a paucity of studies focused on assessing the prevalence, risk factors and characteristics of mild cognitive impairment within the Ghanaian population. This study assessed the prevalence of mild cognitive impairment and explored its relationship with various sociodemographic factors. Methods: A prospective cross-sectional analytical study within Cape Coast, Ghana, evaluating the cognition of 100 participants using the Montreal Cognitive Assessment (MoCA) tool. The prevalence of MCI was determined using simple descriptive measures. The two-way ANOVA was used to determine risk factors for developing MCI. The Pearson correlation coefficient was used to determine the relationship between educational level and MoCA score. Results: A majority (65.4 %) of participants within the age group 40-49 years had mild cognitive impairment. 42.86 % of male and 40.54 % of female participants had MCI (MoCA score < 26). There was a significant correlation (r= 0.608, p= 0.0001) between the educational level of participants and the MoCA score. Participants classified as having MCI based on their MoCA score, performed significantly poorer in visuospatial, attention, language, abstraction and delayed recall domains compared to those with normal cognition. Conclusion: The MoCA tool is a useful for detecting MCI, particularly among Ghanaians with at least 7 years of formal education. The prevalence of MCI among individuals aged 40-49 years in the Cape Coast Metropolis represents an important health burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.